Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab

Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e845-e849. doi: 10.1016/j.clml.2021.06.019. Epub 2021 Jul 14.

Authors

Craig W Freyer¹, Erin M Bange¹, Sarah Skuli¹, Miles Hsu¹, John Lin¹, Adam Cuker¹, Adam D Cohen¹, Alfred Garfall¹

Affiliation

¹ Hospital of the University of Pennsylvania, Philadelphia, PA.

PMID: 34366267
DOI: 10.1016/j.clml.2021.06.019

No abstract available

Keywords: Atypical hemolytic uremic syndrome; Carfilzomib; Eculizumab; Proteasome inhibitor; Thrombotic microangiopathic anemia.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Atypical Hemolytic Uremic Syndrome / chemically induced*
Atypical Hemolytic Uremic Syndrome / drug therapy
Blood Proteins / metabolism*
Complement Factor H / metabolism*
Female
Humans
Middle Aged
Oligopeptides / adverse effects*

Substances

Antibodies, Monoclonal, Humanized
Blood Proteins
CFHR3 protein, human
Oligopeptides
carfilzomib
Complement Factor H
eculizumab